Moleculin Biotech, Inc. (MBRX)
| Previous Close | 4.96 |
| Open | 5.11 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 5.11 - 5.36 |
| 52 Week Range | 0.34 - 6.24 |
| Volume | |
| Avg. Volume | 109,247 |
| Market Cap | 11.472M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -15.15 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.00 |
PR NewswireMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will host a virtual AML Clinical Day on Tuesday, May 7, 2024 at 11:00 AM ET.
PR NewswireMoleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman.
ACCESSWIREMoleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 /JTC Team ("JTC"), a fully integrated corporate communications and investor ...
